临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02034123 | Carcinoma, Small Cell | Phase 1 | Terminated(The risk benefit in... 展开 >> relapsed refractory SCLC does not favor continuation of the study) 收起 << | - | United States, Missouri ... 展开 >> GSK Investigational Site Saint Louis, Missouri, United States, 63110 United States, Ohio GSK Investigational Site Columbus, Ohio, United States, 43210 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 France GSK Investigational Site Villejuif cedex, France, 94805 Spain GSK Investigational Site Barcelona, Spain, 08035 GSK Investigational Site Madrid, Spain, 28034 GSK Investigational Site Madrid, Spain, 28040 GSK Investigational Site Málaga, Spain, 29010 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
0.35mL 0.07mL 0.03mL |
1.75mL 0.35mL 0.17mL |
3.50mL 0.70mL 0.35mL |